Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.

Simple item page
dc.contributor.authorSupapannachart, Sen_US
dc.contributor.authorKhowsathit, Pen_US
dc.contributor.authorPatchakapati, Ben_US
dc.date.accessioned2009-05-27T21:03:26Z
dc.date.available2009-05-27T21:03:26Z
dc.date.issued1999-11-24en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractBACKGROUND: Very low birth weight (VLBW, less than 1500 g) and extremely low birth weight infants (ELBW, less than 1000 g) are the premature infants that are most likely to develop symptomatic PDA. Intravenous indomethacin has proven effective in prevention of PDA in many prospective trials. This strategy will be a useful adjunctive therapy for premature infants in Thailand. OBJECTIVE: To answer the following questions: 1. Will multiple doses of intravenous indomethacin, given to VLBW infants within the first day of life, effectively prevent the occurrence of symptomatic PDA? Are there any side effects or complications? 2. Will this strategy be more beneficial in ELBW? METHODS AND SUBJECTS: The study included thirty VLBW infants born at Ramathibodi Hospital, with birth weights ranging from 630 to 1230 g. They were randomized into 2 groups of 15 infants each. One group received 3 doses of intravenous indomethacin at the dosage of 0.2 mg/kg initially and then 0.1 mg/kg every 12 hours for 2 more doses; the second group received a placebo. The study was performed by a double blind control. RESULTS: Sixteen infants developed symptomatic PDA, 4 in the indomethacin group and 12 in the placebo group. The decrease in incidence of PDA is statistically significant. But when the data was analyzed separately for the VLBW and ELBW groups. The effects were only significantly different in ELBW but not yet significant in the VLBW group. There was a statistically significant difference in the incidence of severe intraventricular hemorrhage (IVH) (grade 3 or higher) in the ELBW infants. CONCLUSION: Intravenous indomethacin therapy given to VLBW infants with a birth weight of less than 1250 g decreased incidence of symptomatic PDA with no significant permanent side effects. The effect was markedly noticeable in ELBW infants. Incidence of severe IVH was also markedly decreased in the ELBW infants who received indomethacin.en_US
dc.description.affiliationDepartment of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.en_US
dc.identifier.citationSupapannachart S, Khowsathit P, Patchakapati B. Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams. Journal of the Medical Association of Thailand. 1999 Nov; 82 Suppl 1(): S87-92en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/44118
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshCyclooxygenase Inhibitors --therapeutic useen_US
dc.subject.meshDuctus Arteriosus, Patent --prevention & controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIndomethacin --therapeutic useen_US
dc.subject.meshInfant, Newbornen_US
dc.subject.meshInfant, Prematureen_US
dc.subject.meshInfant, Premature, Diseases --drug therapyen_US
dc.subject.meshInfant, Very Low Birth Weighten_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.titleIndomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand